Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.

Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.

Publication date: Jul 01, 2020

Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection. Recent evidence accumulates that adamantanes, widely used in different neurological diseases, could be repurposed for COVID-19. We hereby report on a questionnaire-based study performed to assess severity of COVID-19 in patients suffering from multiple sclerosis (n=10), Parkinson’s disease (n=5) or cognitive impairment (n=7). In all patients infection with SARS-CoV-2 was confirmed by rtPCR of nasopharyngeal swabs. They were receiving treatment with either amantadine (n=15) or memantine (n=7) in stable registered doses. All of them had two-week quarantine since documented exposure and none of them developed clinical manifestations of infectious disease. They also did not report any significant changes in neurological status in the course of primary nervous system disease. Above results warrant further studies on protective effects of adamantanes against COVID-19 manifestation, especially in subjects suffering from neurological disease.

Open Access PDF

Concepts Keywords
Amantadine Zoonoses
Cognitive Impairment Coronaviridae
Coronavirus Animal virology
Infection NMDA receptor antagonists
Infectious Disease Amines
Memantine Branches of biology
Multiple Sclerosis Viruses
Nasopharyngeal Psychoactive drugs
Nervous System Widely neurological diseases
Neurological Multiple sclerosis
Neurological Diseases SARS
Pandemic Cognitive impairment
Parkinson Coronavirus
Parkinsonism Amantadine
Quarantine Neurological disorder
Questionnaire
RtPCR
SARS

Semantics

Type Source Name
disease MESH multiple sclerosis
disease MESH cognitive impairment
disease MESH infection
disease MESH suffering
drug DRUGBANK Amantadine
drug DRUGBANK Memantine
disease MESH infectious disease
disease MESH nervous system disease

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *